Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine. Issue 9 (23rd February 2022)

• Record Type: Journal Article
• Authors: Panwar, Kavita; Godi, Anna; Cocuzza, Clementina E.; Andrews, Nick; Southern, Jo; Turner, Paul; Miller, Elizabeth; Beddows, Simon
• Is Part Of: Vaccine. Volume 40:Issue 9(2022)
• Page Start: 1198
• Page End: 1202
• Publication Date: 2022-02-23
• Subjects: Human papillomavirus -- Vaccine -- Antibody -- Durability; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.01.041
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12‐15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.